ArticleEClinicalMedicine2023

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.

Guy de Bruyn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.